← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedcompany
OTO-510 by Otonomy
Also known as: OTO-510
Otonomy
Company
Otonomy
Program Type
Therapeutic
Modality
Small Molecule
Stage
Preclinical
Status
Discontinued
Target Gene
—
Route / Mode
Unknown
Confidence
83%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States
Population
adult, cisplatin-ototoxicity
Trial IDs
0
Mechanism
Novel proprietary otoprotection molecule program intended to prevent cisplatin-induced hearing loss without protecting tumors.
Indications
Notes
Preclinical otoprotection program explicitly positioned against cisplatin ototoxicity; no successor owner was publicly disclosed after Otonomy dissolved.
Evidence & Sources
2 structured sourcesKey Events
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2